Showing results (41-50 of 203) with videos related to

Sort By:
Pageof 21
Pancreas|January 11, 2019
The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic AdenocarcinomaJulien Péron, Joris Giai, Delphine Maucort-Boulch, et al.
BMJ Open|October 17, 2025
Regional variation in clinical-trial risks: a large-scale analysis of 585 clinical trialsSylviane de Viron, Steve Young, Laura Trotta, et al.
International Journal of Clinical Oncology|January 14, 2018
Meta-analysis of randomized clinical trials in the era of individual patient data sharingTakuya Kawahara, Musashi Fukuda, Koji Oba, et al.
Biometrics|August 16, 2011
Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific timeStuart G Baker, Daniel J Sargent, Marc Buyse, et al.
Lifetime Data Analysis|January 22, 2008
Exploring and validating surrogate endpoints in colorectal cancerTomasz Burzykowski, Marc Buyse, Greg Yothers, et al.
Statistics in Medicine|October 13, 2005
A unifying approach for surrogate marker validation based on Prentice's criteriaAriel Alonso, Geert Molenberghs, Helena Geys, et al.
Statistical Methods in Medical Research|August 5, 2016
An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoringJulien Péron, Marc Buyse, Brice Ozenne, et al.
JAMA Oncology|April 29, 2016
The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical TrialsJulien Péron, Pascal Roy, Brice Ozenne, et al.
Pharmaceutical Statistics|April 1, 2025
Detection of Outlying Correlation Coefficients in Multicenter Clinical TrialsLieven Desmet, David Venet, Laura Trotta, et al.
Statistical Methods in Medical Research|July 7, 2017
A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analysesFederico Rotolo, Xavier Paoletti, Tomasz Burzykowski, et al.
Pageof 21